These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 25356580)

  • 1. No studies have shown improved overall survival with maintenance therapy.
    Ujjani C
    Clin Adv Hematol Oncol; 2014 Aug; 12(8):541, 544-6. PubMed ID: 25356580
    [No Abstract]   [Full Text] [Related]  

  • 2. [Subcutaneous Rituximab is effective and safe].
    Häckel A
    Med Monatsschr Pharm; 2014 Jan; 37(1):39-40. PubMed ID: 24490439
    [No Abstract]   [Full Text] [Related]  

  • 3. Maintenance rituximab should be considered for patients with follicular lymphoma.
    Barr PM
    Clin Adv Hematol Oncol; 2014 Aug; 12(8):541-3. PubMed ID: 25356579
    [No Abstract]   [Full Text] [Related]  

  • 4. Maintenance rituximab every 2 months is more toxic than every 3 months in patients with non-Hodgkin lymphoma.
    Rashidi A; Oak E; Bartlett NL
    Blood; 2015 May; 125(21):3354-5. PubMed ID: 25999445
    [No Abstract]   [Full Text] [Related]  

  • 5. Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database.
    Ban-Hoefen M; Vanderplas A; Crosby-Thompson AL; Abel GA; Czuczman MS; Gordon LI; Kaminski MS; Kelly J; Millenson M; Nademanee AP; Rodriguez MA; Zelenetz AD; Niland J; LaCasce AS; Friedberg JW
    Br J Haematol; 2013 Nov; 163(4):487-95. PubMed ID: 24111533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Malignant lymphoma: individualized treatment according to biological and clinical risk factors].
    Dreyling M
    Dtsch Med Wochenschr; 2011 Apr; 136(14):687-90. PubMed ID: 21448827
    [No Abstract]   [Full Text] [Related]  

  • 7. [Lymphatic neoplasias in young patients].
    Borchmann P; Gökbuget N; Wulf G; Trümper L
    Onkologie; 2011; 34 Suppl 5():6-11. PubMed ID: 21921661
    [No Abstract]   [Full Text] [Related]  

  • 8. [Subcutaneous administration of MabThera for therapy of non-Hodgkin lymphomas frees patients and medical personnel].
    Pflege Z; 2013 Apr; 66(4):253. PubMed ID: 23634557
    [No Abstract]   [Full Text] [Related]  

  • 9. Fcγ receptor predictive genomic testing and the treatment of indolent non-Hodgkin lymphoma.
    Treon SP
    Clin Lymphoma Myeloma Leuk; 2010 Oct; 10(5):321-2. PubMed ID: 21030343
    [No Abstract]   [Full Text] [Related]  

  • 10. Rituximab in the treatment of non-Hodgkin's lymphoma--a critical evaluation of randomized controlled trials.
    Griffin MM; Morley N
    Expert Opin Biol Ther; 2013 May; 13(5):803-11. PubMed ID: 23560506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma.
    Molina A
    Annu Rev Med; 2008; 59():237-50. PubMed ID: 18186705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab faster infusion for patients with non-Hodgkin's lymphoma in the United States: implications for nursing practice.
    Dawson K
    J Infus Nurs; 2013; 36(3):172-8. PubMed ID: 23558916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatments for non-Hodgkin lymphoma in HIV-positive patients: quantifying incremental benefit from 1993 to 2004 by metaregression.
    Messori A; Fadda V; Maratea D; Trippoli S
    Am J Hematol; 2013 May; 88(5):435. PubMed ID: 23420571
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmaceutical follow-up for patients on rituximab therapy for non-Hodgkin lymphoma: what is the evidence?
    Hegele V; Stoll P; Wüst D; Ehrenbrink G; Grazziotin LR; Caregnato JP; Lindenmeyer LP
    Int J Clin Pharm; 2013 Aug; 35(4):513-9. PubMed ID: 23737385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for rituximab-induced interstitial lung diseases in patients with malignant lymphoma.
    Cha SI; Choi KJ; Shin KM; Lim J; Yoo SS; Lee J; Lee SY; Kim CH; Park JY
    Respiration; 2013; 85(2):175. PubMed ID: 23234874
    [No Abstract]   [Full Text] [Related]  

  • 16. New therapies in non-Hodgkin lymphoma.
    Novelli S; Sierra J; Briones J
    Expert Rev Anticancer Ther; 2015 Mar; 15(3):349-59. PubMed ID: 25582186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.
    Koo YX; Tay M; Teh YE; Teng D; Tan DS; Tan IB; Tai DW; Quek R; Tao M; Lim ST
    Ann Hematol; 2011 Oct; 90(10):1219-23. PubMed ID: 21520001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct apoptotic signaling characteristics of the anti-CD40 monoclonal antibody dacetuzumab and rituximab produce enhanced antitumor activity in non-Hodgkin lymphoma.
    Lewis TS; McCormick RS; Emmerton K; Lau JT; Yu SF; McEarchern JA; Grewal IS; Law CL
    Clin Cancer Res; 2011 Jul; 17(14):4672-81. PubMed ID: 21610152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituxan delays disease progression in indolent non-Hodgkin's lymphoma.
    Oncology (Williston Park); 2002 Nov; 16(11):1472. PubMed ID: 12469926
    [No Abstract]   [Full Text] [Related]  

  • 20. Rituximab maintenance stretches progression-free survival in patients with indolent NHL.
    Oncology (Williston Park); 2004 Sep; 18(10):1316. PubMed ID: 15526836
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.